miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13

Peijing Zhang, Li Wang, Cristian Rodriguez-Aguayo, Yuan Yuan, Bisrat G. Debeb, Dahu Chen, Yutong Sun, M. James You, Yongqing Liu, Douglas C. Dean, Wendy A. Woodward, Han Liang, Xianbin Yang (), Gabriel Lopez-Berestein, Anil K. Sood, Ye Hu, K. Kian Ang, Junjie Chen and Li Ma ()
Additional contact information
Peijing Zhang: The University of Texas MD Anderson Cancer Center
Li Wang: The University of Texas MD Anderson Cancer Center
Cristian Rodriguez-Aguayo: The University of Texas MD Anderson Cancer Center
Yuan Yuan: The University of Texas MD Anderson Cancer Center
Bisrat G. Debeb: The University of Texas MD Anderson Cancer Center
Dahu Chen: The University of Texas MD Anderson Cancer Center
Yutong Sun: Department of Molecular and Cellular Oncology
M. James You: The University of Texas MD Anderson Cancer Center
Yongqing Liu: Molecular Targets Program, James Graham Brown Cancer Center, University of Louisville Health Sciences Center
Douglas C. Dean: Molecular Targets Program, James Graham Brown Cancer Center, University of Louisville Health Sciences Center
Wendy A. Woodward: The University of Texas MD Anderson Cancer Center
Han Liang: The University of Texas MD Anderson Cancer Center
Xianbin Yang: AM Biotechnologies
Gabriel Lopez-Berestein: The University of Texas MD Anderson Cancer Center
Anil K. Sood: The University of Texas MD Anderson Cancer Center
Ye Hu: Houston Methodist Research Institute
K. Kian Ang: The University of Texas MD Anderson Cancer Center
Junjie Chen: The University of Texas MD Anderson Cancer Center
Li Ma: The University of Texas MD Anderson Cancer Center

Nature Communications, 2014, vol. 5, issue 1, 1-10

Abstract: Abstract Tumour cells associated with therapy resistance (radioresistance and drug resistance) are likely to give rise to local recurrence and distant metastatic relapse. Recent studies revealed microRNA (miRNA)-mediated regulation of metastasis and epithelial–mesenchymal transition; however, whether specific miRNAs regulate tumour radioresistance and can be exploited as radiosensitizing agents remains unclear. Here we find that miR-205 promotes radiosensitivity and is downregulated in radioresistant subpopulations of breast cancer cells, and that loss of miR-205 is highly associated with poor distant relapse-free survival in breast cancer patients. Notably, therapeutic delivery of miR-205 mimics via nanoliposomes can sensitize the tumour to radiation in a xenograft model. Mechanistically, radiation suppresses miR-205 expression through ataxia telangiectasia mutated (ATM) and zinc finger E-box binding homeobox 1 (ZEB1). Moreover, miR-205 inhibits DNA damage repair by targeting ZEB1 and the ubiquitin-conjugating enzyme Ubc13. These findings identify miR-205 as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant tumours.

Date: 2014
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms6671 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6671

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6671

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().